ZA941136B - Novel process for the preparation of cetrorelix lyophilisate - Google Patents

Novel process for the preparation of cetrorelix lyophilisate

Info

Publication number
ZA941136B
ZA941136B ZA941136A ZA941136A ZA941136B ZA 941136 B ZA941136 B ZA 941136B ZA 941136 A ZA941136 A ZA 941136A ZA 941136 A ZA941136 A ZA 941136A ZA 941136 B ZA941136 B ZA 941136B
Authority
ZA
South Africa
Prior art keywords
dried
sterile freeze
cetrorelix
cetrorelix acetate
preparation
Prior art date
Application number
ZA941136A
Other languages
English (en)
Inventor
Juergen Engel
Burkhard Wichert
Dieter Sauerbier
Thomas Reissmann
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6480924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA941136(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA941136B publication Critical patent/ZA941136B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA941136A 1993-02-19 1994-02-18 Novel process for the preparation of cetrorelix lyophilisate ZA941136B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4305225A DE4305225A1 (de) 1993-02-19 1993-02-19 Neues Herstellverfahren für Cetrorelix Lyophilisat

Publications (1)

Publication Number Publication Date
ZA941136B true ZA941136B (en) 1994-08-29

Family

ID=6480924

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941136A ZA941136B (en) 1993-02-19 1994-02-18 Novel process for the preparation of cetrorelix lyophilisate

Country Status (29)

Country Link
EP (2) EP0611572B1 (xx)
JP (1) JP4033919B2 (xx)
KR (2) KR100355686B1 (xx)
CN (1) CN1109557C (xx)
AT (1) ATE193653T1 (xx)
AU (1) AU671881C (xx)
BR (1) BR9400617A (xx)
CA (1) CA2115943C (xx)
CZ (2) CZ285768B6 (xx)
DE (2) DE4305225A1 (xx)
DK (1) DK0611572T3 (xx)
ES (1) ES2148247T3 (xx)
FI (1) FI110059B (xx)
GR (1) GR3034237T3 (xx)
HR (1) HRP940117B1 (xx)
HU (1) HU218281B (xx)
IL (1) IL108704A (xx)
MX (1) MX9401312A (xx)
NO (1) NO316601B1 (xx)
NZ (2) NZ250906A (xx)
PL (1) PL177177B1 (xx)
PT (1) PT611572E (xx)
RU (1) RU2145234C1 (xx)
SG (1) SG46632A1 (xx)
SI (1) SI9400087B (xx)
SK (2) SK283022B6 (xx)
TW (1) TW387812B (xx)
UA (1) UA43829C2 (xx)
ZA (1) ZA941136B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
CZ301912B6 (cs) 1998-04-23 2010-07-28 Zentaris Ivf Gmbh Lécivo na lécení neplodnosti nitrodeložní inseminací
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
US7884071B2 (en) 2002-09-27 2011-02-08 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
CN101629758B (zh) * 2008-07-19 2012-09-26 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
CN101630607B (zh) * 2008-07-19 2012-04-25 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
RU2454221C2 (ru) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Способ получения лиофилизированного противовирусного средства
JP2014502282A (ja) 2010-12-06 2014-01-30 アストロン リサーチ リミテッド 安定な使用準備済みセトロレリックス注射液
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102423484B (zh) * 2011-11-23 2014-01-15 深圳翰宇药业股份有限公司 一种稳定的西曲瑞克药物组合物及其制备方法
EP3015553A1 (de) 2014-10-30 2016-05-04 Biotecon Diagnostics GmbH Stabilisierte Reaktionsmischung
RU2667128C2 (ru) 2016-12-29 2018-09-14 Герман Петрович Беккер Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
US20220233631A1 (en) 2019-06-17 2022-07-28 Intas Pharmaceuticals Ltd. Stable formulation of cetrorelix
CN112717119B (zh) * 2021-01-27 2024-04-30 南京羚诺生物医药技术研究院有限公司 一种西曲瑞克药物组合物及其制备方法
US20240123021A1 (en) 2021-06-25 2024-04-18 Extrovis Ag Pharmaceutical compositions
CN114159544A (zh) * 2022-01-24 2022-03-11 福州华为医药技术开发有限公司 注射用醋酸西曲瑞克及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816386A (en) * 1972-06-20 1974-06-11 Abbott Lab Purification process for gn-rh
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
CS230614B1 (en) * 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
EP0268066A3 (en) * 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
DE3735614A1 (de) * 1986-10-31 1988-07-28 Asta Pharma Ag Ifosfamid-lyophilisat und verfahren zu dessen herstellung
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) * 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法

Also Published As

Publication number Publication date
HU9400481D0 (en) 1994-12-28
EP0947200A2 (de) 1999-10-06
CA2115943C (en) 2003-08-05
CA2115943A1 (en) 1994-08-20
CN1112019A (zh) 1995-11-22
NZ250906A (en) 1997-07-27
NO316601B1 (no) 2004-03-08
SI9400087B (sl) 2002-02-28
ATE193653T1 (de) 2000-06-15
DK0611572T3 (da) 2000-09-25
DE59409389D1 (de) 2000-07-13
EP0611572A3 (de) 1995-01-11
CN1109557C (zh) 2003-05-28
IL108704A0 (en) 1994-05-30
HU218281B (en) 2000-07-28
PT611572E (pt) 2000-11-30
MX9401312A (es) 1994-08-31
EP0611572A2 (de) 1994-08-24
BR9400617A (pt) 1994-09-27
JPH06271476A (ja) 1994-09-27
GR3034237T3 (en) 2000-12-29
SG46632A1 (en) 1998-02-20
EP0947200B1 (de) 2015-03-11
FI110059B (fi) 2002-11-29
SI9400087A (en) 1994-12-31
NO940564L (xx) 1994-08-22
JP4033919B2 (ja) 2008-01-16
SK283021B6 (sk) 2003-02-04
CZ284314B6 (cs) 1998-10-14
HUT67117A (en) 1995-02-28
RU2145234C1 (ru) 2000-02-10
FI940779A (fi) 1994-08-20
AU671881B2 (en) 1996-09-12
KR100355686B1 (ko) 2002-12-11
PL177177B1 (pl) 1999-10-29
KR100372187B1 (ko) 2003-02-14
EP0947200A3 (de) 2004-03-24
NO940564D0 (no) 1994-02-18
NZ314707A (en) 1999-02-25
HRP940117A2 (en) 1996-08-31
ES2148247T3 (es) 2000-10-16
AU671881C (en) 2004-01-15
IL108704A (en) 2005-05-17
AU5523594A (en) 1994-08-25
SK19594A3 (en) 1994-09-07
CZ31294A3 (en) 1994-09-14
FI940779A0 (fi) 1994-02-18
EP0611572B1 (de) 2000-06-07
HRP940117B1 (en) 2001-02-28
TW387812B (en) 2000-04-21
SK283022B6 (sk) 2003-02-04
UA43829C2 (uk) 2002-01-15
DE4305225A1 (de) 1994-08-25
CZ285768B6 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
SG46632A1 (en) Novel process for the preparation of cetrorelix lyophilisate
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
NZ506631A (en) Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization
ZA947894B (en) Compounds for medicinal use
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
AU1290288A (en) A process for treating infertility and an agent for use in the process
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
CA2133441A1 (en) Haemophilus somnus immunogenic proteins
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them
IT1255649B (it) Peptidi dotati di attivita' antibatterica